Neil A. Accortt

2.5k total citations
55 papers, 1.9k citations indexed

About

Neil A. Accortt is a scholar working on Immunology, Rheumatology and Oncology. According to data from OpenAlex, Neil A. Accortt has authored 55 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Immunology, 19 papers in Rheumatology and 15 papers in Oncology. Recurrent topics in Neil A. Accortt's work include Rheumatoid Arthritis Research and Therapies (18 papers), Psoriasis: Treatment and Pathogenesis (8 papers) and Biosimilars and Bioanalytical Methods (8 papers). Neil A. Accortt is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (18 papers), Psoriasis: Treatment and Pathogenesis (8 papers) and Biosimilars and Bioanalytical Methods (8 papers). Neil A. Accortt collaborates with scholars based in United States, Australia and Netherlands. Neil A. Accortt's co-authors include John F. Thompson, Simon Magowan, Harald J. Hoekstra, Anne Brecht Francken, Seng‐Jaw Soong, Helen M. Shaw, Jiajing Chen, Christina Ha, Daniel H. Solomon and Helga Radner and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Internal Medicine and Gastroenterology.

In The Last Decade

Neil A. Accortt

52 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Neil A. Accortt United States 23 618 543 375 286 270 55 1.9k
François Lefrère France 26 822 1.3× 362 0.7× 340 0.9× 111 0.4× 187 0.7× 79 2.9k
Mahmoud Aljurf Saudi Arabia 36 1.2k 1.9× 384 0.7× 633 1.7× 107 0.4× 609 2.3× 234 4.3k
Evarist Feliú Spain 30 682 1.1× 258 0.5× 310 0.8× 236 0.8× 381 1.4× 209 3.0k
Yves Chalandon Switzerland 34 995 1.6× 728 1.3× 761 2.0× 233 0.8× 494 1.8× 192 4.3k
Neelam Varma India 25 405 0.7× 271 0.5× 351 0.9× 210 0.7× 569 2.1× 342 2.9k
Laurent Chiche France 24 311 0.5× 403 0.7× 695 1.9× 743 2.6× 296 1.1× 111 2.3k
Seymour Grufferman United States 28 862 1.4× 521 1.0× 194 0.5× 145 0.5× 251 0.9× 73 2.9k
D Baronciani Italy 29 428 0.7× 455 0.8× 418 1.1× 64 0.2× 260 1.0× 94 3.8k
Jörg Halter Switzerland 33 685 1.1× 839 1.5× 624 1.7× 79 0.3× 281 1.0× 161 3.5k
Estibaliz Lazaro France 30 320 0.5× 348 0.6× 1.1k 2.8× 895 3.1× 461 1.7× 156 2.8k

Countries citing papers authored by Neil A. Accortt

Since Specialization
Citations

This map shows the geographic impact of Neil A. Accortt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil A. Accortt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil A. Accortt more than expected).

Fields of papers citing papers by Neil A. Accortt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil A. Accortt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil A. Accortt. The network helps show where Neil A. Accortt may publish in the future.

Co-authorship network of co-authors of Neil A. Accortt

This figure shows the co-authorship network connecting the top 25 collaborators of Neil A. Accortt. A scholar is included among the top collaborators of Neil A. Accortt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil A. Accortt. Neil A. Accortt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Accortt, Neil A., et al.. (2021). Demographics and clinical characteristics of metastatic colorectal cancer patients treated with bevacizumab-awwb in real-world oncology clinics.. Journal of Clinical Oncology. 39(3_suppl). 90–90. 1 indexed citations
2.
Accortt, Neil A., et al.. (2021). Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer. Future Oncology. 17(36). 5119–5127. 10 indexed citations
3.
Pappas, Dimitrios A., Ying Shan, Greg Kricorian, et al.. (2020). Maintenance of Sustained Low Disease Activity or Remission in Patients With Rheumatoid Arthritis Treated With Etanercept Monotherapy: Results from the Corrona Registry. ACR Open Rheumatology. 2(10). 588–594. 4 indexed citations
4.
Pappas, Dimitrios A., Heather J. Litman, Greg Kricorian, et al.. (2020). Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data. Rheumatology International. 41(2). 381–390. 5 indexed citations
5.
Mease, Philip J., Neil A. Accortt, Sabrina Rebello, et al.. (2019). Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting. Rheumatology International. 39(9). 1547–1558. 8 indexed citations
6.
7.
8.
Mease, Philip J., et al.. (2017). Changes in Treatment Patterns in Patients with Psoriatic Arthritis Initiating Biologic and Nonbiologic Therapy in a Clinical Registry. The Journal of Rheumatology. 44(2). 184–192. 12 indexed citations
9.
10.
Accortt, Neil A., et al.. (2017). Changes in Healthcare Utilization After Etanercept Initiation in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis. Advances in Therapy. 34(9). 2093–2103. 14 indexed citations
11.
Curtis, Jeffrey R., et al.. (2016). OP0259 Impact of Sustained Remission on Risk for Infection in Patients with Rheumatoid Arthritis Enrolled in A Us Registry. Annals of the Rheumatic Diseases. 75. 156–156. 1 indexed citations
12.
Accortt, Neil A., et al.. (2015). Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease‐Modifying Antirheumatic Drugs. Arthritis & Rheumatology. 68(1). 67–76. 19 indexed citations
13.
14.
Ha, Christina, et al.. (2009). Risk of Arterial Thrombotic Events in Inflammatory Bowel Disease. The American Journal of Gastroenterology. 104(6). 1445–1451. 165 indexed citations
15.
Francken, Anne Brecht, Neil A. Accortt, Helen M. Shaw, et al.. (2008). Prognosis and Determinants of Outcome Following Locoregional or Distant Recurrence in Patients with Cutaneous Melanoma. Annals of Surgical Oncology. 15(5). 1476–1484. 73 indexed citations
16.
Zhang, Wenyue, et al.. (2006). Promotion of Acellular Dermal Matrix Resolution In Vitro by Matrix Metalloproteinase-2. Archives of Facial Plastic Surgery. 8(3). 208–212. 10 indexed citations
17.
Chen, Ray Y., Neil A. Accortt, Andrew O. Westfall, et al.. (2006). Distribution of Health Care Expenditures for HIV-Infected Patients. Clinical Infectious Diseases. 42(7). 1003–1010. 124 indexed citations
18.
Leong, Stanley P. L., Neil A. Accortt, Richard Essner, et al.. (2006). Impact of Sentinel Node Status and Other Risk Factors on the Clinical Outcome of Head and Neck Melanoma Patients. Archives of Otolaryngology - Head and Neck Surgery. 132(4). 370–370. 78 indexed citations
19.
Desmond, Renée A., et al.. (2005). Population-based Study of the Geographic Variation in Colon Cancer Incidence in Alabama: Relationship to Socioeconomic Status Indicators and Physician Density. Southern Medical Journal. 98(11). 1076–1082. 18 indexed citations
20.
Accortt, Neil A., John W. Waterbor, Colleen Beall, & George Howard. (2005). Cancer Incidence among a Cohort of Smokeless Tobacco Users (United States). Cancer Causes & Control. 16(9). 1107–1115. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by François Lefrère Breakdown of academic impact, for papers by Mahmoud Aljurf Breakdown of academic impact, for papers by Evarist Feliú Breakdown of academic impact, for papers by Yves Chalandon Breakdown of academic impact, for papers by Neelam Varma Breakdown of academic impact, for papers by Laurent Chiche Breakdown of academic impact, for papers by Seymour Grufferman Breakdown of academic impact, for papers by D Baronciani Breakdown of academic impact, for papers by Jörg Halter Breakdown of academic impact, for papers by Estibaliz Lazaro
Rankless by CCL
2026